Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
This report contains market size and forecasts of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in Global, including the following market information:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market was valued at 14800 million in 2021 and is projected to reach US$ 54520 million by 2028, at a CAGR of 20.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
CellSearch Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) include Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee and Fluxion, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Segment Percentages, by Type, 2021 (%)
CellSearch
Others
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Segment Percentages, by Application, 2021 (%)
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems

LEAVE A REPLY

Please enter your comment!
Please enter your name here